Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 1:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 233 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metabolism and Excretion Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose AME Study With [14C]AR882 in Healthy Male Subjects

NCT04508426
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]AR882
Drug
Lead sponsor
Arthrosi Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 15, 2020 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

NCT04092712
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)

NCT06658626
View directory record Official record
Conditions
Healthy
Interventions
[¹⁴C]Enlicitide chloride
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Radiolabeled Dose Mass Balance Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] Palbociclib (PD-0332991) In Healthy Male Volunteers

NCT01756768
View directory record Official record
Conditions
Healthy
Interventions
[14C]-PD-0332991
Radiation
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Results available

Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease

NCT00296400
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
23
States / cities
Avondale, Arizona • Phoenix, Arizona • Pasadena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RDEA3170 AME Study

NCT01910506
View directory record Official record
Conditions
Healthy
Interventions
RDEA3170 10 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects

NCT01442831
View directory record Official record
Conditions
Healthy
Interventions
Human ADME
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 17, 2026, 1:46 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

NCT00868361
View directory record Official record
Conditions
Healthy
Interventions
Talampanel (non-radiolabeled), [14C] Talampanel
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of [14C]-SKI-O-703 Following a Single Oral Dose in Healthy Male Subjects

NCT05042986
View directory record Official record
Conditions
Healthy Volunteers
Interventions
.[14C]-SKI-O-703
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Patupilone After a Single Intravenous Administration in Patients With Advance Solid Tumor Malignancies.

NCT00426140
View directory record Official record
Conditions
Advanced Malignancies, Solid Tumors
Interventions
Patupilone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356

NCT04147910
View directory record Official record
Conditions
Healthy Male Subjects
Interventions
KW-6356
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006)

NCT07334886
View directory record Official record
Conditions
Healthy
Interventions
[14C]Ulonivirine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 17, 2026, 1:46 AM EDT
Terminated Phase 2 Interventional

ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)

NCT00229684
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Tesaglitazar, pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
21
States / cities
Pasadena, California • Washington D.C., District of Columbia • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2011 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants

NCT04560738
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-CC-92480
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 28, 2021 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional

Oral Nifedipine to Treat Iron Overload

NCT00712738
View directory record Official record
Conditions
Thalassemia, Iron Overload, Hemochromatosis
Interventions
Nifedipine, Phlebotomy, Urinalysis, Echocardiogram, Electrocardiogram
Drug · Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Absorption, Metabolism, and Excretion, of TAK-994 in 6 Healthy Male Adults

NCT04833049
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-994 Oral Tablet, [14C]TAK-994 Intravenous Infusion, [14C]TAK-994 Oral Suspension
Drug
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

NCT06301971
View directory record Official record
Conditions
Healthy Participants
Interventions
Emraclidine
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects

NCT01611467
View directory record Official record
Conditions
Safety and Pharmacokinetics in Healthy Volunteer Subjects
Interventions
CC-223
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Radiolabeled Study of CC-122 in Healthy Subjects

NCT02234999
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-122
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females

NCT00881062
View directory record Official record
Conditions
ABSORPTION, METABOLISM, EXCRETION
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 7, 2014 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers

NCT02030639
View directory record Official record
Conditions
Healthy
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

NCT03811834
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Mobocertinib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 11, 2024 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

NCT02692677
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42756493
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 22, 2017 · Synced Sep 17, 2026, 1:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin in Humans

NCT01969994
View directory record Official record
Conditions
ADME
Interventions
Controlled dietary background, (-)-[2-14C]epicatechin intake
Other
Lead sponsor
The Institutes for Pharmaceutical Discovery, LLC
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Sep 17, 2026, 1:46 AM EDT